Clinical importance of achieving biochemical control with medical therapy in adult patients with acromegaly

References

• Ben-ShlomoAMelmedSAcromegalyEndocrinol Metab Clin North Am2008371101122viii18226732
   PubMed Web of Science ®Google Scholar
• MelmedSAcromegaly pathogenesis and treatmentJ Clin Invest2009119113189320219884662
   PubMed Web of Science ®Google Scholar
• KatznelsonLLawsERJrMelmedSEndocrine SocietyAcromegaly: an endocrine society clinical practice guidelineJ Clin Endocrinol Metab201499113933395125356808
   PubMed Web of Science ®Google Scholar
• HoldawayIMRajasooryaCEpidemiology of acromegalyPituitary199921294111081170
   PubMedGoogle Scholar
• BurtonTLe NestourENearyMLudlamWHIncidence and prevalence of acromegaly in a large US health plan databasePituitary Epub2016120
   Web of Science ®Google Scholar
• RosarioPWFrequency of acromegaly in adults with diabetes or glucose intolerance and estimated prevalence in the general populationPituitary201114321722121170595
   PubMed Web of Science ®Google Scholar
• ChansonPSalenaveSAcromegalyOrphanet J Rare Dis200831718578866
   PubMed Web of Science ®Google Scholar
• AnagnostisPEfstathiadouZAPolyzosSAAcromegaly: presentation, morbidity and treatment outcomes at a single centreInt J Clin Pract201165889690221679284
   PubMed Web of Science ®Google Scholar
• BurtonTLe NestourEBancroftTNearyMReal-world comorbidities and treatment patterns of patients with acromegaly in two large US health plan databasesPituitary201316335436223054327
   PubMed Web of Science ®Google Scholar
• HoldawayIMBollandMJGambleGDA meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegalyEur J Endocrinol20081592899518524797
   PubMed Web of Science ®Google Scholar
• SughrueMEChangEFGabrielRAAghiMKBlevinsLSExcess mortality for patients with residual disease following resection of pituitary adenomasPituitary201114327628321476061
   PubMed Web of Science ®Google Scholar
• HoldawayIMRajasooryaRCGambleGDFactors influencing mortality in acromegalyJ Clin Endocrinol Metab200489266767414764779
   PubMed Web of Science ®Google Scholar
• CarmichaelJDBonertVSNuñoMLyDMelmedSAcromegaly clinical trial methodology impact on reported biochemical efficacy rates of somatostatin receptor ligand treatments: a meta-analysisJ Clin Endocrinol Metab20149951825183324606084
   PubMed Web of Science ®Google Scholar
• KreutzerJVanceMLLopesMBLawsERJrSurgical management of GH-secreting pituitary adenomas: an outcome study using modern remission criteriaJ Clin Endocrinol Metab20018694072407711549628
   PubMed Web of Science ®Google Scholar
• StarkeRMRaperDMPayneSCVanceMLOldfieldEHJaneJAJrEndoscopic vs microsurgical transsphenoidal surgery for acromegaly: outcomes in a concurrent series of patients using modern criteria for remissionJ Clin Endocrinol Metab20139883190319823737543
   PubMed Web of Science ®Google Scholar
• MarquezYTuchmanAZadaGSurgery and radiosurgery for acromegaly: a review of indications, operative techniques, outcomes, and complicationsInt J Endocrinol2012201238640122518121
   PubMed Web of Science ®Google Scholar
• CarlsenSMLund-JohansenMSchreinerTPreoperative Octreotide Treatment of Acromegaly study groupPreoperative octreotide treatment in newly diagnosed acromegalic patients with macroadenomas increases cure short-term postoperative rates: a prospective, randomized trialJ Clin Endocrinol Metab20089382984299018492760
   PubMed Web of Science ®Google Scholar
• ShenMShouXWangYEffect of presurgical long-acting octreotide treatment in acromegaly patients with invasive pituitary macroadenomas: a prospective randomized studyEndocr J201057121035104421099129
   PubMed Web of Science ®Google Scholar
• MaoZGZhuYHTangHLPreoperative lanreotide treatment in acromegalic patients with macroadenomas increases short-term postoperative cure rates: a prospective, randomised trialEur J Endocrinol2010162466166620061334
   PubMed Web of Science ®Google Scholar
• MurrayRDKimKRenSGChellyMUmeharaYMelmedSCentral and peripheral actions of somatostatin on the growth hormone-IGF-I axisJ Clin Invest2004114334935615286801
   PubMed Web of Science ®Google Scholar
• MarinaDBurmanPKloseMTruncated somatostatin receptor 5 may modulate therapy response to somatostatin analogues-observations in two patients with acromegaly and severe headacheGrowth Horm IGF Res201525526226726188991
   PubMed Web of Science ®Google Scholar
• ColaoAAuriemmaRSPivonelloRThe effects of somatostatin analogue therapy on pituitary tumor volume in patients with acromegalyPituitary201619221022126290466
   PubMed Web of Science ®Google Scholar
• FredaPUKatznelsonLvan der LelyAJReyesCMZhaoSRabinowitzDLong-acting somatostatin analog therapy of acromegaly: a meta-analysisJ Clin Endocrinol Metab20059084465447315886238
   PubMed Web of Science ®Google Scholar
• BevanJSClinical review: the antitumoral effects of somatostatin analog therapy in acromegalyJ Clin Endocrinol Metab20059031856186315613435
   PubMed Web of Science ®Google Scholar
• GiustinaAChansonPKleinbergDAcromegaly Consensus GroupExpert consensus document: a consensus on the medical treatment of acromegalyNat Rev Endocrinol201410424324824566817
   PubMed Web of Science ®Google Scholar
• LosaMMortiniPUrbazLRibottoPCastrignanóTGiovanelliMPresurgical treatment with somatostatin analogs in patients with acro-megaly: effects on the remission and complication ratesJ Neurosurg2006104689990616776333
   PubMed Web of Science ®Google Scholar
• BrunsCLewisIBrinerUMeno-TetangGWeckbeckerGSOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profileEur J Endocrinol2002146570771611980628
   PubMed Web of Science ®Google Scholar
• ColaoABronsteinMDFredaPPasireotide C2305 Study GroupPasireotide versus octreotide in acromegaly: a head-to-head superiority studyJ Clin Endocrinol Metab201499379179924423324
   PubMed Web of Science ®Google Scholar
• GadelhaMRBronsteinMDBrueTPasireotide C2402 Study GroupPasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trialLancet Diabetes Endocrinol201421187588425260838
   PubMed Web of Science ®Google Scholar
• TrainerPJDrakeWMKatznelsonLTreatment of acromegaly with the growth hormone-receptor antagonist pegvisomantN Engl J Med2000342161171117710770982
   PubMed Web of Science ®Google Scholar
• Somavert [package insert]New York, NYPfizer2016
   Google Scholar
• van der LelyAJBillerBMBrueTLong-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDYJ Clin Endocrinol Metab20129751589159722362824
   PubMed Web of Science ®Google Scholar
• HodishIBarkanALong-term effects of pegvisomant in patients with acromegalyNat Clin Pract Endocrinol Metab20084632433218431372
   PubMedGoogle Scholar
• HoflandLJFeeldersRAde HerderWWLambertsSWPituitary tumours: the sst/D2 receptors as molecular targetsMol Cell Endocrinol20103261–2899820438803
   PubMed Web of Science ®Google Scholar
• AbsRVerhelstJMaiterDCabergoline in the treatment of acromegaly: a study in 64 patientsJ Clin Endocrinol Metab19988323743789467544
   PubMed Web of Science ®Google Scholar
• GadelhaMRKasukiLKorbonitsMNovel pathway for somatostatin analogs in patients with acromegalyTrends Endocrinol Metab201324523824623270713
   PubMed Web of Science ®Google Scholar
• Duran-PradoMSaveanuALuqueRMA potential inhibitory role for the new truncated variant of somatostatin receptor 5, sst5TMD4, in pituitary adenomas poorly responsive to somatostatin analogsJ Clin Endocrinol Metab20109552497250220233783
   PubMed Web of Science ®Google Scholar
• OriolaJLucasTHalperinIGermline mutations of AIP gene in somatotropinomas resistant to somatostatin analoguesEur J Endocrinol2012168191323038625
   PubMed Web of Science ®Google Scholar
• JalladRSTrarbachEBDuarteFHJorgeAABronsteinMDInfluence of growth hormone receptor (GHR) exon 3 and -202A/C IGFBP-3 genetic polymorphisms on clinical and biochemical features and therapeutic outcome of patients with acromegalyPituitary201518566667325552351
   PubMed Web of Science ®Google Scholar
• FredaPUMonitoring of acromegaly: what should be performed when GH and IGF-1 levels are discrepant?Clin Endocrinol (Oxf)200971216617019226264
   PubMed Web of Science ®Google Scholar
• FeenstraJde HerderWWten HaveSMCombined therapy with somatostatin analogues and weekly pegvisomant in active acromegalyLancet200536594711644164615885297
   PubMed Web of Science ®Google Scholar
• HighamCEAtkinsonABAylwinSEffective combination treatment with cabergoline and low-dose pegvisomant in active acromegaly: a prospective clinical trialJ Clin Endocrinol Metab20129741187119322278424
   PubMed Web of Science ®Google Scholar
• PetrossiansPBorges-MartinsLEspinozaCGross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogsEur J Endocrinol20051521616615762188
   PubMed Web of Science ®Google Scholar
• KaravitakiNTurnerHEAdamsCBSurgical debulking of pituitary macroadenomas causing acromegaly improves control by lanreotideClin Endocrinol (Oxf)200868697097518031313
   PubMed Web of Science ®Google Scholar
• ColaoAAttanasioRPivonelloRPartial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegalyJ Clin Endocrinol Metab2006911859216263832
   PubMed Web of Science ®Google Scholar
• EugsterEAPescovitzOHGigantismJ Clin Endocrinol Metab199984124379438410599691
   PubMed Web of Science ®Google Scholar
• MercadoMGonzalezBVargasGSuccessful mortality reduction and control of comorbidities in patients with acromegaly followed at a highly specialized multidisciplinary clinicJ Clin Endocrinol Metab201499124438444625210882
   PubMed Web of Science ®Google Scholar
• DelaroudisSPEfstathiadouZAKoukoulisGNAmelioration of cardiovascular risk factors with partial biochemical control of acromegalyClin Endocrinol (Oxf)200869227928418194486
   PubMed Web of Science ®Google Scholar
• GurnellMPowlsonASCardiovascular disease and sleep disordered breathing in acromegalyNeuroendocrinology20161031758526227953
   PubMed Web of Science ®Google Scholar
• KepicogluHHatipogluEBulutIDariciEHizliNKadiogluPImpact of treatment satisfaction on quality of life of patients with acromegalyPituitary201417655756324337714
   PubMed Web of Science ®Google Scholar
• MangupliRCamperosPWebbSMBiochemical and quality of life responses to octreotide-LAR in acromegalyPituitary201417649549924178448
   PubMed Web of Science ®Google Scholar
• PaisleyANRowlesSVRobertsMETreatment of acromegaly improves quality of life, measured by AcroQolClin Endocrinol (Oxf)200767335836217555502
   PubMed Web of Science ®Google Scholar
• MattaMPCoutureECazalsLVezzosiDBennetACaronPImpaired quality of life of patients with acromegaly: control of GH/IGF-I excess improves psychological subscale appearanceEur J Endocrinol2008158330531018299462
   PubMed Web of Science ®Google Scholar
• Leon-CarrionJMartin-RodriguezJFMadrazo-AtutxaAEvidence of cognitive and neurophysiological impairment in patients with untreated naive acromegalyJ Clin Endocrinol Metab20109594367437920554710
   PubMed Web of Science ®Google Scholar
• TiemensmaJBiermaszNRvan der MastRCIncreased psychopathology and maladaptive personality traits, but normal cognitive functioning, in patients after long-term cure of acromegalyJ Clin Endocrinol Metab20109512E392E40220843947
   PubMed Web of Science ®Google Scholar
• CaronPJBevanJSPetersennSPRIMARYS InvestigatorsTumor shrinkage with lanreotide autogel 120 mg as primary therapy in acromegaly: results of a prospective multicenter clinical trialJ Clin Endocrinol Metab20149941282129024423301
   PubMed Web of Science ®Google Scholar
• NeggersSJvan AkenMOde HerderWWQuality of life in acromegalic patients during long-term somatostatin analog treatment with and without pegvisomantJ Clin Endocrinol Metab200893103853385918647806
   PubMed Web of Science ®Google Scholar
• PlöckingerUMedical therapy of acromegalyInt J Endocrinol2012201226895722550484
   PubMed Web of Science ®Google Scholar
• FleseriuMAdvances in the pharmacotherapy of patients with acromegalyDiscov Med2014179632933824979253
   PubMed Web of Science ®Google Scholar
• RobertsJLindenMCervinCTibergFOctreotide fluid crystal provides sustained octreotide bioavailability and similar IGF1 suppression to that of octreotide LAR (Sandostatin LAR): randomized, open-label, phase 1, repeat-dose study in healthy volunteers [abstract P914]Endocr Abstr201435329
   Google Scholar
• TibergFRobertsJCervinCOctreotide s.c. depot provides sustained octreotide bioavailability and similar IGF-1 suppression to octreotide LAR in healthy volunteersBr J Clin Pharmacol201580346047226076191
   PubMed Web of Science ®Google Scholar
• MelmedSPopovicVBidlingmaierMSafety and efficacy of oral octreotide in acromegaly: results of a multicenter phase III trialJ Clin Endocrinol Metab201510041699170825664604
   PubMed Web of Science ®Google Scholar
• DuarteFHJalladRSBronsteinMDClomiphene citrate for treatment of acromegaly not controlled by conventional therapiesJ Clin Endocrinol Metab201510051863186925738590
   PubMed Web of Science ®Google Scholar